Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT02889900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.
Study identification
- NCT ID
- NCT02889900
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2017 (Actual)
- Primary completion
- Aug 27, 2019 (Actual)
- Completion
- Mar 16, 2021 (Actual)
- Last update posted
- Mar 8, 2022
2017 – 2021
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36604 | — |
| Research Site | Anchorage | Alaska | 99508 | — |
| Research Site | Downey | California | 90241 | — |
| Research Site | Greenbrae | California | 94904 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Miami | Florida | 33176 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Augusta | Georgia | 30901 | — |
| Research Site | Newnan | Georgia | 30265 | — |
| Research Site | Fort Wayne | Indiana | 46804 | — |
| Research Site | Westwood | Kansas | 66205 | — |
| Research Site | Covington | Louisiana | 70433 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Billings | Montana | 59101 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02889900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02889900 live on ClinicalTrials.gov.